Forecasting and Preventing Post-Bariatric Hypoglycaemia WP 2

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-18

Study Completion Date

2022-07-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The overall aim of this study is to develop a sustainable hypoglycemia correction strategy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Forecasting and Preventing Post-Bariatric Hypoglycaemia WP 1

NCT05212207

Post-bariatric Hypoglycaemia Roux-en-Y Gastric Bypass

COMPLETED

Forecasting and Preventing Post-Bariatric Hypoglycaemia WP 3

NCT05216926

Post-bariatric Hypoglycaemia Roux-en-Y Gastric Bypass

COMPLETED NA

Hybrid Closed Loop Insulin Pump and Bariatric Surgery in Patients With Type 1 Diabetes

NCT06294704

Bariatric Surgery Type 1 Diabetes

COMPLETED

Evaluation of the Neuro-endocrine Response to Post-prandial Hyperinsulinaemic Hypoglycaemia.

NCT04334161

Roux-en-y Gastric Bypass Post Prandial Hypoglycemia

COMPLETED

Glycemic Patterns After Bariatric Surgery and High Glycemic Variability and Hypoglycemia Unawareness Risk Factors

NCT05728320

Bariatric Surgery

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Obesity is a major global public health concern, for which the most effective therapy is bariatric surgery. Beyond weight loss, bariatric surgery exerts powerful effects on glucose metabolism, achieving complete type 2 diabetes remission in up to 70% of cases. An exaggeration of these effects, however, can result in an increasingly recognized metabolic complication known as postprandial hyperinsulinaemic hypoglycaemia or post-bariatric hypoglycaemia (PBH). The condition manifests 1-3 years after surgery with meal-induced hypoglycaemic episodes. Emerging data suggests that PBH is more frequent than previously thought and affects approximately 30% of postoperative patients, more commonly after gastric bypass than sleeve gastrectomy. Of note, asymptomatic PBH is common, as shown in studies using continuous glucose monitoring (CGM). It is known from extensive research in people with diabetes that recurrent episodes of hypoglycaemia impair counter regulatory defences against subsequent events, predisposing patients to severe hypoglycaemia.

Despite the increasing prevalence of PBH, clinical implications in this population are still unclear. Anecdotal evidence from patients with PBH suggests a high burden for these patients due to the recurrent hypoglycaemias with possibly debilitating consequences. It is well established that even mild hypoglycaemia (plasma glucose of 3.4 mmol/L) in diabetic and non-diabetic patients impairs various cognitive domains. Of note, some of the cognitive functions remain impaired for up to 75 min, even when the hypoglycaemia is corrected. Further concerns exist from observational studies showing associations between PBH during pregnancy and poor foetal growth.

Thus, it is important to timely detect and treat hypoglycaemia with an intervention that allows quick recovery of glycaemia to a safe level, thereby alleviating symptoms and eliminating the risk of potentially hazardous sequelae. Current diabetes-inspired guidelines recommend to correct hypoglycaemia with 15-20 g fast-acting carbohydrates, preferably glucose. However, clinical experience with PBH patients shows that the rapid spikes in glycaemia following correction of hypoglycaemia with such proposed strategies may trigger rebound hypoglycaemia in PBH patients. However, hypoglycaemia correction strategies that are tailored to the specific needs of PBH do not exist currently. Previous research suggests that glucose co-ingested with amino acids induces a metabolic environment that could be favourable for PBH patients due to elevated glucagon levels. However, it currently remains speculative whether combinations of amino acids with glucose could offer more suitable and sustainable PBH correction strategies.

Given the potentially hazardous consequences of hypoglycaemia, development of hypoglycaemia management strategies to adequately predict and treat critical blood glucose levels in the PBH population are urgently needed. Such strategies have to significantly lower the burden of PBH and increase patient safety.

The overall aim or the PBH forecast project (containing 3 WPs) is to prevent hypoglycaemic events in patients with PBH and to develop a sustainable hypoglycaemia correction strategy. The primary objective of WP 2 is to test different nutritional strategies for sustainable hypoglycaemia correction (e.g. minimising time spent hypoglycaemic without causing rebound hyper- and hypoglycaemia).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Post-bariatric Hypoglycaemia Roux-en-Y Gastric Bypass

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

3-period crossover design

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Participants

Participants are blinded to sensor and plasma glucose.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment sequence 1

Sequence of the treatments: Glucose (15g) - Glucose (5g) -Protein bar

Group Type OTHER

15 g dextrose

Intervention Type OTHER

15 g dextrose tablets

5 g dextrose

Intervention Type OTHER

5 g dextrose tablets

Protein bar

Intervention Type OTHER

5 g carbohydrates + 10 g protein

Treatment sequence 2

Sequence of the treatments: Glucose (15g) - Protein bar - Glucose (5g)

Group Type OTHER

15 g dextrose

Intervention Type OTHER

15 g dextrose tablets

5 g dextrose

Intervention Type OTHER

5 g dextrose tablets

Protein bar

Intervention Type OTHER

5 g carbohydrates + 10 g protein

Treatment sequence 3

Sequence of the treatments: Glucose (5g) - Glucose (15g) - Protein bar

Group Type OTHER

15 g dextrose

Intervention Type OTHER

15 g dextrose tablets

5 g dextrose

Intervention Type OTHER

5 g dextrose tablets

Protein bar

Intervention Type OTHER

5 g carbohydrates + 10 g protein

Treatment sequence 4

Sequence of the treatments: Glucose (5g) - Protein bar - Glucose (15g)

Group Type OTHER

15 g dextrose

Intervention Type OTHER

15 g dextrose tablets

5 g dextrose

Intervention Type OTHER

5 g dextrose tablets

Protein bar

Intervention Type OTHER

5 g carbohydrates + 10 g protein

Treatment sequence 5

Sequence of the treatments: Protein bar - Glucose (15g) - Glucose (5g)

Group Type OTHER

15 g dextrose

Intervention Type OTHER

15 g dextrose tablets

5 g dextrose

Intervention Type OTHER

5 g dextrose tablets

Protein bar

Intervention Type OTHER

5 g carbohydrates + 10 g protein

Treatment sequence 6

Sequence of the treatments: Protein bar - Glucose (5g) - Glucose (15g)

Group Type OTHER

15 g dextrose

Intervention Type OTHER

15 g dextrose tablets

5 g dextrose

Intervention Type OTHER

5 g dextrose tablets

Protein bar

Intervention Type OTHER

5 g carbohydrates + 10 g protein

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

15 g dextrose

15 g dextrose tablets

Intervention Type OTHER

5 g dextrose

5 g dextrose tablets

Intervention Type OTHER

Protein bar

5 g carbohydrates + 10 g protein

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Post-bariatric surgery patients (Roux-en-Y gastric bypass) with PBH, defined as postprandial plasma or sensor glucose \<3.0 mmol/L according to the International Hypoglycaemia Study Group and exclusion of other causes of hypoglycaemia
* Age ≥18 years

Exclusion Criteria

* Inability to give informed consent as documented by signature
* Pregnant or lactating women
* Inability or contraindications to undergo the investigated intervention
* Drugs interfering with blood glucose (e.g. SGLT-2 inhibitors, acarbose) during the time of investigation
* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No